Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients with psoriasis can have higher rates of hypertension, diabetes mellitus 2, and dyslipidemia. This study aimed to assess the association between psoriasis, myocardial infarction (MI), and stroke. A systematic review was carried out using PubMed/Medline, EMBASE, and LILACS databases searching for observational studies that assessed stroke and/or MI in patients diagnosed with psoriasis vulgaris compared to non-psoriatic patients. A total of 649 articles were identified but only 15 were included in the study. Although there were studies that have observed a significant positive association between psoriasis and MI or stroke, an almost equal number of studies showed no statistically significant association. The relationship between psoriasis and ischemic cardiovascular events is still controversial and it is difficult to establish psoriasis as the etiology of these events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ancard.2022.11.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
J Am Coll Cardiol
September 2025
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region of China; Advanced Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region of China
Background: There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population.
Objectives: In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM.
Methods: We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database.
Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.
J Am Coll Cardiol
September 2025
Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Background: The hemodynamic effects of femoro-femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO) on pulmonary capillary wedge pressure (PCWP) remain poorly defined. High ECMO flow is believed to increase PCWP and the risk of pulmonary edema; yet, supporting in vivo physiological data are lacking.
Objectives: The purpose of this study was to evaluate the impact of incremental femoro-femoral VA-ECMO flow variations on PCWP, hemodynamic, and echocardiographic parameters in patients with cardiogenic shock during the early phase of VA-ECMO support, after stabilization.
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
Heart
September 2025
Department of Cardiology, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.
Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.
Major adverse thrombotic events and bleeding in stage 4-5 chronic kidney disease and dialysis-dependent end-stage kidney disease.
J Thromb Haemost
September 2025
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA.
Background: Balancing the risks of thrombotic and bleeding events in people with advanced kidney disease is a clinical challenge.
Objectives: To estimate rates of major adverse thrombotic events (MATEs) and bleeding events in individuals with chronic kidney disease (CKD) stages 4 or 5 or with end-stage kidney disease (ESKD) receiving hemodialysis (HD) or peritoneal dialysis (PD).
Methods: Using administrative claims from a 20% Medicare sample, Optum's de-identified Clinformatics Data Mart Database, and the US Renal Data System from 2016-2019, we identified individuals with CKD stages 4 or 5 and individuals with dialysis-dependent ESKD.
CCTA-quantified pericornary inflammation and lipoprotein (a): Combined predictive value in non-obstructive CAD.
Int J Cardiol
September 2025
Department of Radiology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, China; Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China. Electronic address:
Objective: This study aimed to enhance major adverse cardiovascular events (MACEs) prediction by pericoronary adipose tissue attenuation (PCATa) in non-obstructive coronary artery disease (CAD) patients when combined with lipoprotein (a) (Lp(a)).
Methods: A total of 1052 patients with non-obstructive CAD were included. Detailed clinical data and CCTA features were analyzed.